title: Editorial perspective. Should microalbuminuria ever be considered as a renal endpoint in any clinical trial?
authors.affiliation: University of Maryland School of Medicine, Baltimore, MD, USA.
authors.forename: Matthew R
authors.initials: MR
authors.lastname: Weir
authors.forename: George L
authors.initials: GL
authors.lastname: Bakris
mesh_terms: D000419:Albuminuria / Q000175:diagnosis*; D015415:Biomarkers; D002986:Clinical Trials as Topic / Q000592:standards*; D015331:Cohort Studies; D003928:Diabetic Nephropathies / Q000652:urine*; D006801:Humans; D007249:Inflammation; D007674:Kidney Diseases / Q000628:therapy / Q000652:urine*; D012107:Research Design; D012307:Risk Factors; D016896:Treatment Outcome
chemical_list: D015415:Biomarkers